Align Technology Slides After Downgrade Points to Softer Demand

Align Technology (ALGN) is down 3.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be an analyst downgrade that highlighted a weaker consumer backdrop, softer dental demand in the third quarter, and a noticeable slowdown in September indicators for the company’s clear aligner business. With the next earnings report set for late October, the market seems to be reacting quickly to any sign that near-term growth could be under pressure.

Details:

One Wall Street firm cut its rating on the stock to a neutral stance and sharply reduced its price target, citing weaker demand trends and possible 2027 headwinds.

The downgrade pointed to a meaningful weakening in the dental macro environment during the third quarter, which matters because orthodontic treatment is often tied to discretionary spending.

Align’s most recent quarterly update showed record revenue and aligner shipments, but North America was only stable while international markets carried more of the growth.

The company recently said it will report third-quarter 2026 results on October 28, which may be making investors more sensitive to any fresh read on demand before earnings.

Sources:

TipRanks, Align Technology Investor Relations, SEC

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive ALGN Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$ALGN Hedge Fund Activity

We have seen 271 institutional investors add shares of $ALGN stock to their portfolio, and 336 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

GOLDMAN SACHS GROUP INC added 1,576,509 shares (+87.8%) to their portfolio in Q2 2026, for an estimated $265,894,007
FMR LLC added 1,359,673 shares (+50.4%) to their portfolio in Q2 2026, for an estimated $229,322,448
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,197,353 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $201,945,556
JPMORGAN CHASE & CO added 773,182 shares (+inf%) to their portfolio in Q2 2026, for an estimated $130,404,876
UBS GROUP AG added 720,131 shares (+51.2%) to their portfolio in Q2 2026, for an estimated $121,457,294
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 668,129 shares (+inf%) to their portfolio in Q2 2026, for an estimated $112,686,637
CAPITAL WORLD INVESTORS removed 649,911 shares (-16.0%) from their portfolio in Q2 2026, for an estimated $109,613,989

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$ALGN Analyst Ratings

Wall Street analysts have issued reports on $ALGN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Evercore ISI Group issued a "Outperform" rating on 04/30/2026

To track analyst ratings and price targets for $ALGN, check out Quiver Quantitative's $ALGN forecast page.

$ALGN Price Targets

Multiple analysts have issued price targets for $ALGN recently. We have seen 5 analysts offer price targets for $ALGN in the last 6 months, with a median target of $220.0.

Here are some recent targets:

Vik Chopra from BMO Capital set a target price of $209.0 on 07/09/2026
Elizabeth Anderson from Evercore ISI Group set a target price of $220.0 on 04/30/2026
Erin Wright from Morgan Stanley set a target price of $188.0 on 04/24/2026
Jason Bednar from Piper Sandler set a target price of $235.0 on 04/21/2026
Daniel Grosslight from Citigroup set a target price of $240.0 on 04/15/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.